CARLOS DRIGGS: Open Payments
NPI 1437741402 · BRONX, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$669 in 28 payments from 12 companies in 2025. Trend: 2023 $460 · 2024 $683 · 2025 $669
Food & beverage: $669
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $126 |
| AstraZeneca Pharmaceuticals LP | 4 | $95 |
| Xeris Pharmaceuticals, Inc. | 4 | $93 |
| Esperion Therapeutics, Inc. | 3 | $85 |
| Lilly USA, LLC | 3 | $65 |
| Ardelyx, Inc. | 2 | $45 |
| Dexcom, Inc. | 2 | $44 |
| Astellas Pharma US Inc | 1 | $33 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $24 |
Products named: Ozempic, AIRSUPRA, RECORLEV, NEXLETOL, MOUNJARO, IBSRELA, Dexcom G6 Transmitter, Veozah.
Industry payments across NY — which companies pay providers there.
